• English
    • Ελληνικά
  • English 
    • English
    • Ελληνικά
  • Login
Browsing by Subject 
  •   Home
  • Browsing by Subject
  •   Home
  • Browsing by Subject
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browsing by Subject "Prostate specific antigen"

  • 0-9
  • Α
  • Β
  • Γ
  • Δ
  • Ε
  • Ζ
  • Η
  • Θ
  • Ι
  • Κ
  • Λ
  • Μ
  • Ν
  • Ξ
  • Ο
  • Π
  • Ρ
  • Σ
  • Τ
  • Υ
  • Φ
  • Χ
  • Ψ
  • Ω
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sort by:

Order:

Results:

Now showing items 1-13 of 13

  • title
  • submit date
  • accessioned date
  • ascending
  • descending
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
    • Article  

      Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: Pilot study of an effective subtoxic therapy 

      Karavasilis, V.; Briassoulis, E. Ch; Siarabi, O.; Pavlidis, Nicholas (2003)
      Taxane-based chemotherapy has shown activity but also toxicity when administered at standard doses in patients with hormone-resistant prostate cancer (HRPC). In this pilot study, we investigated biweekly low-dose docetaxel ...

    • Article  

      Cancer of unknown primary origin 

      Briassoulis, E. Ch; Pavlidis, Nicholas (1997)
      About 3 % of all cancer patients suffer from cancer of unknown primary origin. These patients present with metastatic disease for which a primary site cannot be detected at the time of diagnosis. Sophisticated diagnostic ...

    • Article  

      Cancer of unknown primary: Biological and clinical characteristics 

      Pavlidis, Nicholas (2003)

    • Article  

      Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 

      Fizazi, K.; Greco, F. A.; Pavlidis, Nicholas; Pentheroudakis, George (2011)

    • Article  

      Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 

      Pavlidis, Nicholas; Briassoulis, E. Ch; Pentheroudakis, George (2010)

    • Article  

      Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment and follow-up 

      Briassoulis, E. Ch; Pavlidis, Nicholas; Felip, E. (2009)

    • Article  

      Cancers of unknown primary site: ESMO Clinical Recommendations for diagnosis, treatment and follow-up 

      Briassoulis, E. Ch; Pavlidis, Nicholas (2007)

    • Article  

      Carcinoma of unknown primary (CUP) 

      Pavlidis, Nicholas; Fizazi, K. (2009)
      Carcinoma of unknown primary (CUP) is one of the 10 most frequent cancers worldwide. It constitutes 3-5% of all human malignancies. Patients with CUP present with metastases without an established primary site. CUP manifests ...

    • Article  

      Endometrioid Carcinoma of the Prostate. The Diagnostic Value of Leu7 and Prostatic Specific Antigen 

      Stavropoulos, N. E.; Ioachim, E.; Sidoni, K.; Stefanou, D. G.; Klouvas, G. D.; Pavlidis, Nicholas (1993)
      Summary— In a case of endometrioid carcinoma of the prostate the expression of Leu7 and prostatic specific antigen (PSA) was studied immunohistochemically on paraffin sections. The same markers were studied in 14 cases of ...

    • Article  

      ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP) 

      Briassoulis, E. Ch; Ch, F. Tolis; Pavlidis, Nicholas (2001)

    • Article  

      Forty years experience of treating cancer of unknown primary 

      Pavlidis, Nicholas (2007)
      Cancer of unknown primary site (CUP) is not a rare tumour. It accounts as the seventh to eighth most frequently diagnosed cancer in a general medical oncology service. Since CUP is not a homogeneous disease and it consists ...

    • Article  

      Long-term survivors among patients with cancer of unknown primary 

      Pavlidis, Nicholas; Petrakis, Dimitrios; Golfinopoulos, Vassilis; Pentheroudakis, George (2012)
      There is a general conception among oncologists that CUP patients behave poorly to treatment and carry a dismal survival. In this paper we are trying to elucidate the different groups of CUP patients and to describe in ...

    • Article  

      Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets 

      Pavlidis, Nicholas (2012)
      Cancer of unknown primary sites (CUP) is a compilation of various malignant entities-the majority of which behave aggressively and carry poor prognosis. CUP is classified into two different clinicopathological groups: the ...

      Browse

      EverywhereCommunities & CollectionsBy Submission DateAuthorsTitlesSubjectsBy TypeBy DepartmentBy Faculty

      My Account

      Login
      Πνευματικά δικαιώματα ©  Βιβλιοθήκη Πανεπιστημίου Κύπρου
      Contact Us | Send Feedback
      Οδηγίες κατάθεσης διδακτορικής διατριβής
      Open Access
      ORCiD